Loading company
Just reported
Q3 2026 results
From Indivior Pharmaceuticals's results release of October 29, 2026; its quarterly report has since been filed.
Revenue
Actual
$356M
+13% y/y
+3.8% q/qGuided
—
No guide given
EPS, GAAP
Actual
$1.12
+239% y/y
+14% q/qGuided
—
No guide given
Operating income, GAAP
Actual
$180M
+319% y/y
+13% q/qGuided
—
No guide given
Company outlook
Full year 2026
- Revenue$1.295B – $1.365B+7.3% y/y Raised +6.4%
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Indivior Pharmaceuticals is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Drug Manufacturers Specialty and Generic
Graded A or B and worth $2B or more: A first, then the largest.
TAKTakeda Pharmaceutical Company Limited$33.5BA
NBIXNeurocrine Biosciences, Inc.$17.6BA+
ELANElanco Animal Health Incorporated$13.2BA
KNSAKiniksa Pharmaceuticals International, plc$8.1BA+
LQDALiquidia Corporation$5BA
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher CorporationOct 21, 2026CBGraded C, now B
MCKMckesson CorporationNov 4, 2026BAGraded B, now A
CVSCVS Health CorpNov 4, 2026BAGraded B, now A
EWEdwards Lifesciences CorporationNov 4, 2026BAGraded B, now A
BIIBBiogen Inc.Oct 28, 2026BAGraded B, now A
How it makes money
- SUBLOCADE monthly buprenorphine injections74%
- Sublingual buprenorphine medicines25%
Shares of revenue are estimates for six months ended June 30, 2026, not figures from a filing.
Competes with
- CAMXCamurus
- Braeburn
- ALKSAlkermesC
- Size
- $8B
- Margin
- -0.0%
What it sells4
SUBLOCADE
An extended-release buprenorphine injection given under the skin once a month by a health care professional to treat OUD.
SUBOXONE Film
A film containing buprenorphine and naloxone that dissolves under the tongue or against the inside of the cheek to treat OUD.
SUBUTEX Tablet
A buprenorphine tablet that dissolves under the tongue to treat OUD; sold mainly in Australia, France and Germany.
SUBOXONE Tablet
A buprenorphine-and-naloxone tablet for OUD that Indivior continues to sell on a limited transition basis in some countries.
Who buys it4
- Pharmaceutical wholesalers buy medicines from Indivior and distribute them to pharmacies, hospitals and other health care customers; its three largest customers together accounted for 51% of global net revenue (2025, high).
- Specialty pharmacies and distributors handle medicines that require controlled storage or delivery, including SUBLOCADE.
- Hospitals, addiction treatment centers and other organized health systems purchase or arrange access to medicines for patients receiving care.
- Government and private health insurers reimburse for treatment, while health care professionals prescribe or administer the medicines.
What it stands on, and what could break it
What the business leans on
- 1SUBLOCADE accounted for 74% of net revenue (six months ended June 30, 2026, high), making sales dependent on that product.
- 2The United States accounted for 85% of net revenue (2025, high).
- 3Indivior makes the buprenorphine active ingredient at its Hull, United Kingdom plant, but relies on Curia to manufacture SUBLOCADE.
- 4Aquestive is the exclusive global manufacturer and primary packager of SUBOXONE Film.
- 5The three largest U.S. wholesale customers accounted for 51% of global net revenue (2025, high).
What could go wrong
- 1Sales depend heavily on SUBLOCADE; competing long-acting buprenorphine medicines and generic competition for other products could reduce sales or put pressure on prices.
- 2Reliance on outside manufacturers and packagers creates a risk that production or regulatory problems could interrupt supply; buprenorphine supply also depends on controlled-substance import and distribution rules.
- 3Changes to insurance coverage, government reimbursement or rules for controlled medicines could limit patient access or reduce what Indivior receives for its medicines.
About Indivior Pharmaceuticals, Inc.
Indivior makes prescription medicines for opioid use disorder (OUD), a condition involving harmful opioid use. Its main product, SUBLOCADE, is a monthly injection given by a health care professional; other medicines dissolve under the tongue or inside the cheek. The company sells mainly in the United States, with sales also in Canada, Australia, France and Germany.
- Head office
- Richmond, Virginia, United States
- Founded
- 2014
- Listed on
- Nasdaq
- Financial year ends
- December 31
Built from Indivior Pharmaceuticals, Inc.’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
